Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.
The presentation will be webcast live and may be accessed via a link in the News section of the Neurona website under Events. An archived copy of the webcast will be available on the website for approximately 30 days after the event.
About Neurona
Neurona’s regenerative cell therapy candidates have single-dose curative potential. Neurona is developing off-the-shelf, allogeneic neural cell therapy candidates that are designed to provide long-term repair of dysfunctional neural networks for multiple neurological disorders. Neurona has an ongoing multicenter, Phase I/II clinical trial of its lead program, NRTX-1001, designed to evaluate the safety and efficacy of a single administration of inhibitory neuronal cell therapy for drug-resistant Mesial Temporal Lobe Epilepsy. For more information on the clinical trial, please visit www.clinicaltrials.gov (NCT05135091). For more information about Neurona, visit www.neuronatherapeutics.com
Investor and Media Contacts:
| Sylvia Wheeler Wheelhouse LSA [email protected] |
Elizabeth Wolffe, Ph.D. Wheelhouse LSA [email protected] |
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
